



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Claudin-4 [KM3900] Standard Size Ab03415-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: KM3900

Alternative Name(s) of Target: CLDN4; Claudin 4; Clostridium perfringens enterotoxin receptor; CPE-R; CPE-receptor; Williams-Beuren syndrome chromosomal region 8 protein; FERM BP-10751

UniProt Accession Number of Target Protein: O14493

Published Application(s): IP, neutralizing, therapeutic, FC

Published Species Reactivity: Human

Immunogen: The original antibody was generated from BXSb mice immunized with pancreatic cancer cells.

Specificity: The antibody specifically recognizes the conformational structure and binds to extracellular loop 2 of CLDN4. The antibody does not react with denatured CLDN4 protein. The antibody does not cross react with CLDN3, 5, 6, and 9. Claudin-4 is a tetraspanin transmembrane protein of tight junction structure and is highly expressed in pancreatic and ovarian cancers.

Application Notes: Cell lysates were prepared from pancreatic cancer cells (Capan-2 and HPAF-II) and CLDN/CHO cells, and subjected to immunoprecipitation analysis. The antibody was shown to specifically precipitate CLDN4. This antibody detected CLDN4 expressed on CHO cells by flow cytometry. Furthermore, binding of the antibody was detected on CLDN4-expressing pancreatic and ovarian cancer cells, but not on negative cells. Moreover, the chimeric IgG1 (KM3934) version of the antibody was made and its antitumor efficacy was evaluated. KM3934 induced dose-dependent antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, and significantly inhibited tumor growth in MCAS or CFPAC-1 xenograft SCID mice in vivo (Suzuki et al., 2009; PMID:1955390). The antibody strongly bound to the CLDN4 expressed in breast cancer cells, colorectal cancer cells and prostate cancer cells. The antibody inhibited the cell movement ability of CLDN4 expression cells. The antibody showed neutralizing activity for CLDN4 (US8076458).

Antibody First Published in: Suzuki et al. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers Cancer Sci. 2009 Sep;100(9):1623-30. PMID:1955390

Note on publication: The original paper describes the generation and characterization of the antibody.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.